Literature DB >> 20333489

Preparation and characterization of inclusion complexes of a hemisuccinate ester prodrug of delta9-tetrahydrocannabinol with modified beta-cyclodextrins.

Sampada B Upadhye1, Swapnil J Kulkarni, Soumyajit Majumdar, Mitchell A Avery, Waseem Gul, Mahmoud A ElSohly, Michael A Repka.   

Abstract

Delta(9)-Tetrahydrocannabinol hemisuccinate (THC-HS), an ester prodrug of Delta(9)-tetrahydrocannabinol (THC) has been investigated for its potential to form inclusion complexes with modified synthetic beta-cyclodextrins (CDs). Phase solubility studies were performed to determine the stoichiometric ratio of complexation of THC-HS with random methylated beta-cyclodextrin (RAMEB) and 2-hydroxypropyl beta-cyclodextrin (HPBCD). THC-HS/RAMEB and THC-HS/HPBCD solid systems were prepared by lyophilization and the lyophilized complexes were characterized by Fourier transform infrared (FT-IR) spectroscopy, proton nuclear magnetic spectroscopy, and molecular modeling techniques. The formation of inclusion complexes of THC-HS/RAMEB and THC-HS/HPBCD was demonstrated by an A(L) type curve with the slopes less than unity by the phase solubility method. The association constants for THC-HS/RAMEB and THC-HS/HPBCD were found to be 562.48 and 238.83 M(-1), respectively. The stoichiometry of both of the complexes was found to be 1:1 as determined from the Job's plot. This was confirmed by (1)H NMR and FT-IR techniques. The results obtained from the molecular modeling studies were in accordance with the data obtained from nuclear magnetic resonance and FT-IR. The docking studies revealed the most probable mode of binding of THC-HS with RAMEB in which the alkyl chain was submerged in the hydrophobic pocket of the CD molecule and hydrogen bonding interactions were observed between the hemisuccinate ester side chain of THC-HS and the rim hydroxy groups of RAMEB. The solubility of THC-HS was significantly higher in RAMEB compared to HPBCD. Solid dispersions of THC-HS with CDs will be further utilized to develop oral formulations of THC-HS with enhanced bioavailability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333489      PMCID: PMC2902337          DOI: 10.1208/s12249-010-9401-4

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  38 in total

Review 1.  Recent progress in cannabinoid research.

Authors:  Julia Adam; Phillip M Cowley; Takao Kiyoi; Angus J Morrison; Christopher J W Mort
Journal:  Prog Med Chem       Date:  2006

Review 2.  Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?

Authors:  Joachim Brouwers; Marcus E Brewster; Patrick Augustijns
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

3.  Polymeric systems for amorphous Delta9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability.

Authors:  Manish Munjal; Mahmoud A Elsohly; Michael A Repka
Journal:  J Pharm Sci       Date:  2006-11       Impact factor: 3.534

Review 4.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

Review 5.  Cannabis: pharmacology and toxicology in animals and humans.

Authors:  I B Adams; B R Martin
Journal:  Addiction       Date:  1996-11       Impact factor: 6.526

6.  Improvements of dissolution characteristics and chemical stability of 16,16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester by cyclodextrin complexation.

Authors:  K Uekama; F Hirayama; Y Yamada; K Inaba; K Ikeda
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

7.  Complexation study of midazolam hydrochloride with beta-cyclodextrin: NMR spectroscopic study in solution.

Authors:  Syed Mashhood Ali; Santosh Kumar Upadhyay
Journal:  Magn Reson Chem       Date:  2008-07       Impact factor: 2.447

8.  Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

Authors:  Donald I Abrams; Joan F Hilton; Roslyn J Leiser; Starley B Shade; Tarek A Elbeik; Francesca T Aweeka; Neal L Benowitz; Barry M Bredt; Bradley Kosel; Judith A Aberg; Steven G Deeks; Thomas F Mitchell; Kathleen Mulligan; Peter Bacchetti; Joseph M McCune; Morris Schambelan
Journal:  Ann Intern Med       Date:  2003-08-19       Impact factor: 25.391

Review 9.  The utility of cyclodextrins for enhancing oral bioavailability.

Authors:  Rebecca L Carrier; Lee A Miller; Imran Ahmed
Journal:  J Control Release       Date:  2007-08-16       Impact factor: 9.776

10.  Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.

Authors:  H Arima; T Kondo; T Irie; K Uekama
Journal:  J Pharm Sci       Date:  1992-11       Impact factor: 3.534

View more
  2 in total

1.  Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy.

Authors:  Tushar Hingorani; Waseem Gul; Mahmoud Elsohly; Michael A Repka; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2011-10-11       Impact factor: 3.534

2.  Development of Fenofibrate/Randomly Methylated β-Cyclodextrin-Loaded Eudragit® RL 100 Nanoparticles for Ocular Delivery.

Authors:  Soe Yadanar Khin; Hay Man Saung Hnin Soe; Chaisak Chansriniyom; Natapol Pornputtapong; Rathapon Asasutjarit; Thorsteinn Loftsson; Phatsawee Jansook
Journal:  Molecules       Date:  2022-07-25       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.